Cathepsin E Prevents Tumor Growth and Metastasis by Catalyzing the Proteolytic Release of Soluble TRAIL from Tumor Cell Surface
The aspartic proteinase cathepsin E is expressed predominantly in cells of the immune system and highly secreted by activated phagocytes, and deficiency of cathepsin E in mice results in a phenotype affecting immune responses. However, because physiologic substrates for cathepsin E have not yet been...
Saved in:
Published in | Cancer research (Chicago, Ill.) Vol. 67; no. 22; pp. 10869 - 10878 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Philadelphia, PA
American Association for Cancer Research
15.11.2007
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The aspartic proteinase cathepsin E is expressed predominantly in cells of the immune system and highly secreted by activated phagocytes, and deficiency of cathepsin E in mice results in a phenotype affecting immune responses. However, because physiologic substrates for cathepsin E have not yet been identified, the relevance of these observations to the physiologic functions of this protein remains speculative. Here, we show that cathepsin E specifically induces growth arrest and apoptosis in human prostate carcinoma tumor cell lines without affecting normal cells by catalyzing the proteolytic release of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) from the cell surface. The antitumor activity of cathepsin E was corroborated by in vivo studies with mice bearing human and mouse tumor transplants. Administration of purified cathepsin E into human tumor xenografts in nude mice dose-dependently induced apoptosis in the tumor cells to inhibit tumor growth. The growth, viability, and metastasis of mouse B16 melanoma cells were also more profound in cathepsin E-deficient mice compared with those in the syngeneic wild-type and transgenic mice overexpressing cathepsin E. Taken together, the number of apoptotic tumor cells, as well as tumor-infiltrating activated macrophages, was apparently reduced in cathepsin E-deficient mice compared with those in the other two groups, implying the positive correlation of endogenous cathepsin E levels with the extent of tumor suppression in vivo. These results thus indicate that cathepsin E plays a substantial role in host defense against tumor cells through TRAIL-dependent apoptosis and/or tumor-associated macrophage-mediated cytotoxicity. |
---|---|
AbstractList | The aspartic proteinase cathepsin E is expressed predominantly in cells of the immune system and highly secreted by activated phagocytes, and deficiency of cathepsin E in mice results in a phenotype affecting immune responses. However, because physiologic substrates for cathepsin E have not yet been identified, the relevance of these observations to the physiologic functions of this protein remains speculative. Here, we show that cathepsin E specifically induces growth arrest and apoptosis in human prostate carcinoma tumor cell lines without affecting normal cells by catalyzing the proteolytic release of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) from the cell surface. The antitumor activity of cathepsin E was corroborated by in vivo studies with mice bearing human and mouse tumor transplants. Administration of purified cathepsin E into human tumor xenografts in nude mice dose-dependently induced apoptosis in the tumor cells to inhibit tumor growth. The growth, viability, and metastasis of mouse B16 melanoma cells were also more profound in cathepsin E-deficient mice compared with those in the syngeneic wild-type and transgenic mice overexpressing cathepsin E. Taken together, the number of apoptotic tumor cells, as well as tumor-infiltrating activated macrophages, was apparently reduced in cathepsin E-deficient mice compared with those in the other two groups, implying the positive correlation of endogenous cathepsin E levels with the extent of tumor suppression in vivo. These results thus indicate that cathepsin E plays a substantial role in host defense against tumor cells through TRAIL-dependent apoptosis and/or tumor-associated macrophage-mediated cytotoxicity. The aspartic proteinase cathepsin E is expressed predominantly in cells of the immune system and highly secreted by activated phagocytes, and deficiency of cathepsin E in mice results in a phenotype affecting immune responses. However, because physiologic substrates for cathepsin E have not yet been identified, the relevance of these observations to the physiologic functions of this protein remains speculative. Here, we show that cathepsin E specifically induces growth arrest and apoptosis in human prostate carcinoma tumor cell lines without affecting normal cells by catalyzing the proteolytic release of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) from the cell surface. The antitumor activity of cathepsin E was corroborated by in vivo studies with mice bearing human and mouse tumor transplants. Administration of purified cathepsin E into human tumor xenografts in nude mice dose-dependently induced apoptosis in the tumor cells to inhibit tumor growth. The growth, viability, and metastasis of mouse B16 melanoma cells were also more profound in cathepsin E-deficient mice compared with those in the syngeneic wild-type and transgenic mice overexpressing cathepsin E. Taken together, the number of apoptotic tumor cells, as well as tumor-infiltrating activated macrophages, was apparently reduced in cathepsin E-deficient mice compared with those in the other two groups, implying the positive correlation of endogenous cathepsin E levels with the extent of tumor suppression in vivo. These results thus indicate that cathepsin E plays a substantial role in host defense against tumor cells through TRAIL-dependent apoptosis and/or tumor-associated macrophage-mediated cytotoxicity. [Cancer Res 2007; 67(22):10869-78] Abstract The aspartic proteinase cathepsin E is expressed predominantly in cells of the immune system and highly secreted by activated phagocytes, and deficiency of cathepsin E in mice results in a phenotype affecting immune responses. However, because physiologic substrates for cathepsin E have not yet been identified, the relevance of these observations to the physiologic functions of this protein remains speculative. Here, we show that cathepsin E specifically induces growth arrest and apoptosis in human prostate carcinoma tumor cell lines without affecting normal cells by catalyzing the proteolytic release of soluble tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) from the cell surface. The antitumor activity of cathepsin E was corroborated by in vivo studies with mice bearing human and mouse tumor transplants. Administration of purified cathepsin E into human tumor xenografts in nude mice dose-dependently induced apoptosis in the tumor cells to inhibit tumor growth. The growth, viability, and metastasis of mouse B16 melanoma cells were also more profound in cathepsin E–deficient mice compared with those in the syngeneic wild-type and transgenic mice overexpressing cathepsin E. Taken together, the number of apoptotic tumor cells, as well as tumor-infiltrating activated macrophages, was apparently reduced in cathepsin E–deficient mice compared with those in the other two groups, implying the positive correlation of endogenous cathepsin E levels with the extent of tumor suppression in vivo. These results thus indicate that cathepsin E plays a substantial role in host defense against tumor cells through TRAIL-dependent apoptosis and/or tumor-associated macrophage-mediated cytotoxicity. [Cancer Res 2007;67(22):10869–78] |
Author | KAWAKUBO, Tomoyo OKAMOTO, Yoshiko YASUKOCHI, Atsushi NAKAYAMA, Keiichi I YAMAMOTO, Kenji OKAMOTO, Kuniaki IWATA, Jun-Ichi KADOWAKI, Tomoko SHIN, Masashi TSUKUBA, Takayuki |
Author_xml | – sequence: 1 givenname: Tomoyo surname: KAWAKUBO fullname: KAWAKUBO, Tomoyo organization: Department of Pharmacology, Graduate School of Dental Science, Kyushu University, United States – sequence: 2 givenname: Kuniaki surname: OKAMOTO fullname: OKAMOTO, Kuniaki organization: Department of Dental Pharmacology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan – sequence: 3 givenname: Jun-Ichi surname: IWATA fullname: IWATA, Jun-Ichi organization: Department of Pharmacology, Graduate School of Dental Science, Kyushu University, United States – sequence: 4 givenname: Masashi surname: SHIN fullname: SHIN, Masashi organization: Department of Pharmacology, Graduate School of Dental Science, Kyushu University, United States – sequence: 5 givenname: Yoshiko surname: OKAMOTO fullname: OKAMOTO, Yoshiko organization: Department of Biochemistry, Daiichi University College of Pharmaceutical Sciences, Fukuoka, Japan – sequence: 6 givenname: Atsushi surname: YASUKOCHI fullname: YASUKOCHI, Atsushi organization: Department of Pharmacology, Graduate School of Dental Science, Kyushu University, United States – sequence: 7 givenname: Keiichi I surname: NAKAYAMA fullname: NAKAYAMA, Keiichi I organization: Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, United States – sequence: 8 givenname: Tomoko surname: KADOWAKI fullname: KADOWAKI, Tomoko organization: Department of Pharmacology, Graduate School of Dental Science, Kyushu University, United States – sequence: 9 givenname: Takayuki surname: TSUKUBA fullname: TSUKUBA, Takayuki organization: Department of Pharmacology, Graduate School of Dental Science, Kyushu University, United States – sequence: 10 givenname: Kenji surname: YAMAMOTO fullname: YAMAMOTO, Kenji organization: Department of Pharmacology, Graduate School of Dental Science, Kyushu University, United States |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19889352$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/18006832$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkc1u1DAURi1URKeFRwB5A7sU_8SJsxxFpVQaCmqHtXXtuaFBiT3YSdGw4dXxqBFdVrJkWTrn-ur7zsiJDx4JecvZBedKf2SM6UKVtbhw4AtWF4KV-gVZcSV1UZelOiGr_8wpOUvpZ34qztQrcso1Y5WWYkX-tjDd4z71nl7SbxEf0E-JbucxRHoVw-_pnoLf0S84QcqnT9QeaHZgOPzp_Q-a5ayFCcNwmHpHb3FASEhDR-_CMNsB6fZ2fb2hXQzjMrfFYaB3c-zA4WvysoMh4ZvlPiffP11u28_F5uvVdbveFE5VbCpkZ0vg3HZKqUqA0hI4Nk3D0FoBlXDAGeelAifQ6h23SjFVOal3ZWmFrOU5-fA4dx_DrxnTZMY-ubwIeAxzMpVWrGq0fBYUrBI8Z5pB9Qi6GFKK2Jl97EeIB8OZOVZkjvGbY_ymXd8YVptjRdl7t3ww2xF3T9bSSQbeLwAkB0MXwbs-PXGN1o1UQv4DAzmbvA |
CODEN | CNREA8 |
CitedBy_id | crossref_primary_10_1016_j_jmb_2008_12_028 crossref_primary_10_1038_s41467_017_02731_6 crossref_primary_10_1002_adbi_201800232 crossref_primary_10_1515_bc_2011_060 crossref_primary_10_1002_ijc_26032 crossref_primary_10_1016_j_pharmthera_2019_02_003 crossref_primary_10_1016_S1349_0079_11_80015_0 crossref_primary_10_1007_s00262_019_02368_y crossref_primary_10_3390_cancers15102752 crossref_primary_10_1016_j_pan_2019_09_009 crossref_primary_10_1016_j_bbapap_2020_140465 crossref_primary_10_1186_s12929_016_0276_x crossref_primary_10_3389_fimmu_2017_00203 crossref_primary_10_3390_cancers11070954 crossref_primary_10_1016_j_job_2011_10_001 crossref_primary_10_1089_acm_2011_0467 crossref_primary_10_3389_fimmu_2023_1209249 crossref_primary_10_3390_ijms18061227 crossref_primary_10_4049_immunohorizons_2000098 crossref_primary_10_1155_2011_834525 crossref_primary_10_1371_journal_pone_0056766 crossref_primary_10_1093_jb_mvr135 crossref_primary_10_1016_j_ajpath_2012_01_023 crossref_primary_10_1111_j_1471_4159_2008_05242_x crossref_primary_10_1186_s12974_017_0891_9 crossref_primary_10_1111_febs_15637 crossref_primary_10_1016_j_bbrc_2008_10_034 crossref_primary_10_1515_bc_2010_087 crossref_primary_10_1002_2211_5463_13372 crossref_primary_10_1177_10915818211069270 crossref_primary_10_3390_cancers11050639 crossref_primary_10_1111_acel_13565 crossref_primary_10_4049_jimmunol_1102173 crossref_primary_10_1016_j_semcancer_2019_05_006 crossref_primary_10_3109_15412555_2015_1057273 crossref_primary_10_1007_s00018_010_0469_5 crossref_primary_10_1371_journal_pone_0132477 crossref_primary_10_1016_j_cbpc_2017_11_005 crossref_primary_10_1039_C7NR01469D crossref_primary_10_1371_journal_pone_0125816 crossref_primary_10_1093_molehr_gau008 crossref_primary_10_1155_2012_316432 crossref_primary_10_3390_cancers11040568 crossref_primary_10_1038_s41598_019_38809_y crossref_primary_10_1159_000488770 crossref_primary_10_3892_ijo_2013_1790 crossref_primary_10_1007_s00109_013_1021_5 crossref_primary_10_1074_jbc_M109_035105 crossref_primary_10_1016_j_ccell_2021_05_005 crossref_primary_10_1245_s10434_014_4155_y crossref_primary_10_3390_biomedicines12010079 crossref_primary_10_1002_psc_2453 crossref_primary_10_1021_pr300758c crossref_primary_10_1016_j_cellimm_2023_104718 crossref_primary_10_3390_cancers10030077 crossref_primary_10_1016_j_dci_2020_103607 crossref_primary_10_3389_fimmu_2019_01530 crossref_primary_10_1016_j_bbapap_2011_05_022 crossref_primary_10_1016_j_toxlet_2017_03_008 crossref_primary_10_3390_cells13060521 crossref_primary_10_1158_0008_5472_CAN_07_5154 crossref_primary_10_3349_ymj_2010_51_5_653 crossref_primary_10_1097_MPA_0000000000000610 crossref_primary_10_1093_carcin_bgt373 |
Cites_doi | 10.1515/BC.2005.036 10.1001/archsurg.136.7.804 10.1002/(SICI)1521-4141(199805)28:05<1492::AID-IMMU1492>3.0.CO;2-X 10.1007/978-3-0348-8737-3_5 10.1002/eji.1830220626 10.1126/science.281.5381.1305 10.1093/oxfordjournals.jbchem.a003247 10.1002/path.1584 10.1111/j.1432-1033.1978.tb12772.x 10.1158/1078-0432.CCR-05-0259 10.1084/jem.189.8.1343 10.1021/bi992242l 10.1006/cimm.2001.1896 10.1016/j.cell.2006.01.007 10.1111/j.1365-2613.2006.00478.x 10.1038/sj.emboj.7600464 10.1084/jem.189.9.1451 10.1016/S1097-2765(00)80207-5 10.1093/jb/mvj132 10.1016/S0304-3835(98)00299-7 10.1159/000090154 10.1126/science.6879183 10.1046/j.1471-4159.1998.70052045.x 10.4049/jimmunol.163.10.5358 10.1093/jb/mvg216 10.1038/385729a0 10.1084/jem.190.8.1155 10.1158/1078-0432.CCR-04-2409 10.1016/S0952-7915(98)80224-0 10.1074/jbc.M108382200 10.1016/S1074-7613(00)80100-4 10.1016/1074-7613(95)90057-8 10.1002/jlb.64.4.419 10.1084/jem.193.6.727 10.1038/nrc1821 10.4049/jimmunol.174.4.1791 10.1074/jbc.M909721199 10.1074/jbc.M604143200 10.1002/(SICI)1521-4141(199803)28:03<973::AID-IMMU973>3.0.CO;2-T 10.1038/sj.cr.7290236 10.1097/00008390-199201000-00001 10.4049/jimmunol.163.4.1906 10.1074/jbc.271.22.12687 10.2330/joralbiosci.48.218 10.2152/jmi.52.1 10.1016/0304-4165(89)90130-X 10.4049/jimmunol.141.7.2407 |
ContentType | Journal Article |
Copyright | 2008 INIST-CNRS |
Copyright_xml | – notice: 2008 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TO H94 7X8 |
DOI | 10.1158/0008-5472.can-07-2048 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Oncogenes and Growth Factors Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Oncogenes and Growth Factors Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE Oncogenes and Growth Factors Abstracts CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1538-7445 |
EndPage | 10878 |
ExternalDocumentID | 10_1158_0008_5472_CAN_07_2048 18006832 19889352 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -ET .55 .GJ 08R 18M 29B 2WC 34G 39C 3O- 476 53G 5GY 5RE 5VS 6J9 8WZ A6W AAPBV AAUGY ABOCM ABPTK ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW ADNWM AENEX AETEA AFFNX AFHIN AFOSN AFRAH AI. ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW C1A CS3 D0S DIK DU5 EBS EJD F5P FRP GX1 H13 IH2 IQODW J5H KQ8 L7B LSO MVM OHT OK1 P0W P2P PQQKQ RCR RHF RHI RNS SJN TR2 UDS VH1 W2D W8F WH7 WHG WOQ X7M XFK XJT YKV YZZ ZA5 ZCG ZGI CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TO H94 7X8 |
ID | FETCH-LOGICAL-c560t-3fb4a11bf55562a583a1e9990ebb2a62ca101145ac2eb8d1b55056c38d44b2373 |
ISSN | 0008-5472 |
IngestDate | Fri Oct 25 21:52:14 EDT 2024 Fri Oct 25 01:37:58 EDT 2024 Thu Sep 26 17:49:20 EDT 2024 Sat Sep 28 07:48:21 EDT 2024 Sun Oct 29 17:07:12 EDT 2023 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 22 |
Keywords | Enzyme Cathepsin E Cytokine Soluble form Metastasis Malignant tumor Cell surface Prevention Peptidases Tumor growth Tumor necrosis factor Hydrolases TNF related apoptosis inducing ligand Aspartic endopeptidases Tumor cell Cancer |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c560t-3fb4a11bf55562a583a1e9990ebb2a62ca101145ac2eb8d1b55056c38d44b2373 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://aacr.figshare.com/articles/journal_contribution/Supplementary_Materials_from_Cathepsin_E_Prevents_Tumor_Growth_and_Metastasis_by_Catalyzing_the_Proteolytic_Release_of_Soluble_TRAIL_from_Tumor_Cell_Surface/22371227/1/files/39816323.pdf |
PMID | 18006832 |
PQID | 20621547 |
PQPubID | 23462 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_68506983 proquest_miscellaneous_20621547 crossref_primary_10_1158_0008_5472_CAN_07_2048 pubmed_primary_18006832 pascalfrancis_primary_19889352 |
PublicationCentury | 2000 |
PublicationDate | 2007-11-15 |
PublicationDateYYYYMMDD | 2007-11-15 |
PublicationDate_xml | – month: 11 year: 2007 text: 2007-11-15 day: 15 |
PublicationDecade | 2000 |
PublicationPlace | Philadelphia, PA |
PublicationPlace_xml | – name: Philadelphia, PA – name: United States |
PublicationTitle | Cancer research (Chicago, Ill.) |
PublicationTitleAlternate | Cancer Res |
PublicationYear | 2007 |
Publisher | American Association for Cancer Research |
Publisher_xml | – name: American Association for Cancer Research |
References | 2022061623363084900_B30 2022061623363084900_B33 2022061623363084900_B34 2022061623363084900_B31 2022061623363084900_B32 2022061623363084900_B37 2022061623363084900_B38 2022061623363084900_B35 2022061623363084900_B36 2022061623363084900_B39 2022061623363084900_B22 2022061623363084900_B23 2022061623363084900_B20 2022061623363084900_B21 2022061623363084900_B26 2022061623363084900_B27 2022061623363084900_B24 2022061623363084900_B25 2022061623363084900_B28 2022061623363084900_B29 2022061623363084900_B1 2022061623363084900_B5 2022061623363084900_B4 2022061623363084900_B3 2022061623363084900_B2 2022061623363084900_B50 2022061623363084900_B11 2022061623363084900_B12 2022061623363084900_B10 2022061623363084900_B15 2022061623363084900_B16 2022061623363084900_B13 2022061623363084900_B14 2022061623363084900_B19 2022061623363084900_B17 2022061623363084900_B18 2022061623363084900_B40 2022061623363084900_B41 2022061623363084900_B44 2022061623363084900_B45 2022061623363084900_B42 2022061623363084900_B43 2022061623363084900_B9 2022061623363084900_B48 2022061623363084900_B8 2022061623363084900_B49 2022061623363084900_B7 2022061623363084900_B46 2022061623363084900_B6 2022061623363084900_B47 |
References_xml | – ident: 2022061623363084900_B21 doi: 10.1515/BC.2005.036 – ident: 2022061623363084900_B45 doi: 10.1001/archsurg.136.7.804 – ident: 2022061623363084900_B40 doi: 10.1002/(SICI)1521-4141(199805)28:05<1492::AID-IMMU1492>3.0.CO;2-X – ident: 2022061623363084900_B3 doi: 10.1007/978-3-0348-8737-3_5 – ident: 2022061623363084900_B6 doi: 10.1002/eji.1830220626 – ident: 2022061623363084900_B15 doi: 10.1126/science.281.5381.1305 – ident: 2022061623363084900_B22 doi: 10.1093/oxfordjournals.jbchem.a003247 – ident: 2022061623363084900_B11 doi: 10.1002/path.1584 – ident: 2022061623363084900_B23 doi: 10.1111/j.1432-1033.1978.tb12772.x – ident: 2022061623363084900_B14 doi: 10.1158/1078-0432.CCR-05-0259 – ident: 2022061623363084900_B30 doi: 10.1084/jem.189.8.1343 – ident: 2022061623363084900_B27 doi: 10.1021/bi992242l – ident: 2022061623363084900_B44 – ident: 2022061623363084900_B43 doi: 10.1006/cimm.2001.1896 – ident: 2022061623363084900_B48 doi: 10.1016/j.cell.2006.01.007 – ident: 2022061623363084900_B47 doi: 10.1111/j.1365-2613.2006.00478.x – ident: 2022061623363084900_B50 doi: 10.1038/sj.emboj.7600464 – ident: 2022061623363084900_B39 doi: 10.1084/jem.189.9.1451 – ident: 2022061623363084900_B19 doi: 10.1016/S1097-2765(00)80207-5 – ident: 2022061623363084900_B9 doi: 10.1093/jb/mvj132 – ident: 2022061623363084900_B34 doi: 10.1016/S0304-3835(98)00299-7 – ident: 2022061623363084900_B12 doi: 10.1159/000090154 – ident: 2022061623363084900_B36 doi: 10.1126/science.6879183 – ident: 2022061623363084900_B33 doi: 10.1046/j.1471-4159.1998.70052045.x – ident: 2022061623363084900_B41 doi: 10.4049/jimmunol.163.10.5358 – ident: 2022061623363084900_B8 doi: 10.1093/jb/mvg216 – ident: 2022061623363084900_B38 doi: 10.1038/385729a0 – ident: 2022061623363084900_B32 doi: 10.1084/jem.190.8.1155 – ident: 2022061623363084900_B13 doi: 10.1158/1078-0432.CCR-04-2409 – ident: 2022061623363084900_B28 doi: 10.1016/S0952-7915(98)80224-0 – ident: 2022061623363084900_B4 doi: 10.1074/jbc.M108382200 – ident: 2022061623363084900_B18 doi: 10.1016/S1074-7613(00)80100-4 – ident: 2022061623363084900_B16 doi: 10.1016/1074-7613(95)90057-8 – ident: 2022061623363084900_B29 doi: 10.1002/jlb.64.4.419 – ident: 2022061623363084900_B49 doi: 10.1084/jem.193.6.727 – ident: 2022061623363084900_B2 doi: 10.1038/nrc1821 – ident: 2022061623363084900_B7 doi: 10.4049/jimmunol.174.4.1791 – ident: 2022061623363084900_B26 doi: 10.1074/jbc.M909721199 – ident: 2022061623363084900_B42 – ident: 2022061623363084900_B10 doi: 10.1074/jbc.M604143200 – ident: 2022061623363084900_B20 doi: 10.1002/(SICI)1521-4141(199803)28:03<973::AID-IMMU973>3.0.CO;2-T – ident: 2022061623363084900_B25 – ident: 2022061623363084900_B24 doi: 10.1038/sj.cr.7290236 – ident: 2022061623363084900_B37 doi: 10.1097/00008390-199201000-00001 – ident: 2022061623363084900_B31 doi: 10.4049/jimmunol.163.4.1906 – ident: 2022061623363084900_B17 doi: 10.1074/jbc.271.22.12687 – ident: 2022061623363084900_B46 doi: 10.2330/joralbiosci.48.218 – ident: 2022061623363084900_B1 doi: 10.2152/jmi.52.1 – ident: 2022061623363084900_B5 doi: 10.1016/0304-4165(89)90130-X – ident: 2022061623363084900_B35 doi: 10.4049/jimmunol.141.7.2407 |
SSID | ssj0005105 |
Score | 2.2503726 |
Snippet | The aspartic proteinase cathepsin E is expressed predominantly in cells of the immune system and highly secreted by activated phagocytes, and deficiency of... Abstract The aspartic proteinase cathepsin E is expressed predominantly in cells of the immune system and highly secreted by activated phagocytes, and... |
SourceID | proquest crossref pubmed pascalfrancis |
SourceType | Aggregation Database Index Database |
StartPage | 10869 |
SubjectTerms | Animals Antineoplastic agents Apoptosis Biological and medical sciences Carcinoma - metabolism Cathepsin E - metabolism Cell Membrane - metabolism Humans Immune System Male Medical sciences Mice Mice, Inbred C57BL Mice, Transgenic Models, Biological Neoplasm Metastasis Neoplasms - metabolism Pharmacology. Drug treatments Prostatic Neoplasms - metabolism TNF-Related Apoptosis-Inducing Ligand - metabolism Tumors |
Title | Cathepsin E Prevents Tumor Growth and Metastasis by Catalyzing the Proteolytic Release of Soluble TRAIL from Tumor Cell Surface |
URI | https://www.ncbi.nlm.nih.gov/pubmed/18006832 https://search.proquest.com/docview/20621547 https://search.proquest.com/docview/68506983 |
Volume | 67 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6FIiEkhHgTHmUP3CKH-LF-HKMoqLSkAppKvVm79lqpmtpRYitKL_xFfhIzu2s7KS2iXKzEzo6tzOfdmdn5Zgj5GDHOuMOFldqRsLxMcku4dmq5MoskhzVXpCpB9tg_OPUOz9hZp_NrK2upKkU_ubqRV_I_WoVzoFdkyd5Bs41QOAGfQb9wBA3D8Z90rOh7C_D2e-OeqcW06k2ry2KJMaW1Ya1NZMnBBsTKI2BrjjBes7mqWVLfsE5DMd-UKqF-jps1mscyr5BTNf0x_PJVc1C03BHG-k6qZcaT61UOErnsmdpBM7U5rLM81Cw0n_e3Yg5HfM0vKqEuTYvLYlM0sd4LDthRF46q_BzM2wa7a64N3cMqt86TWXPhZKbLIEz4ChtD7YQxAuTzaSJnMzWHFvN0H5--bGfjwNP1JuvpWnfvMLDUnGYz-WLTqGhrJYfvuj3Qn8sEC3Vepb5lfzQ8xngtFjFu18U6F-DactkkMSr3iYW4fR_GKCYGMfEgiFHMPXLfwdKDmCbwva1fz0xSbX1nwykDMZ9ufJoda-nRgq_gxc10x5XbXSJlGk2fkMfGp6FDDdCnpCPzZ-TBxGRtPCc_G5zSMa1xShWeqMYpBZzSFqdUbGiLUwqD6RZOqcEpLTJqcEoVTini1MhFnFKD0xfk9PN4OjqwTOMPKwEDvLTcTHjctkXGGJjnnIUutyV4MgMphMN9J-E2-vGMJ44UYWoLdLP9xA1TzxOOG7gvyV5e5PI1oTAijYQdiEGUeb4PxhiLwIeOvMgXrkz9LunXf3C80PVd4r8qtkv2d9TQjopCsP2Z0yUfar3EMFXj_hvPZVGtYLgPBrYX3P4LH-tHRqHbJa-0QlvpIZK5XOfNXZ_3LXnYvm7vyF65rOR7sKNLsa-g-RucHMKx |
link.rule.ids | 315,783,787,27937,27938 |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cathepsin+E+Prevents+Tumor+Growth+and+Metastasis+by+Catalyzing+the+Proteolytic+Release+of+Soluble+TRAIL+from+Tumor+Cell+Surface&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=Kawakubo%2C+Tomoyo&rft.au=Okamoto%2C+Kuniaki&rft.au=Iwata%2C+Jun-ichi&rft.au=Shin%2C+Masashi&rft.date=2007-11-15&rft.issn=0008-5472&rft.eissn=1538-7445&rft.volume=67&rft.issue=22&rft.spage=10869&rft.epage=10878&rft_id=info:doi/10.1158%2F0008-5472.CAN-07-2048&rft.externalDBID=n%2Fa&rft.externalDocID=10_1158_0008_5472_CAN_07_2048 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-5472&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-5472&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-5472&client=summon |